HLX43
Based on 1 Customer Validation
HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1. HLX43 consists of a human monoclonal antibody anti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.60%
- Peso molecular:153714 (average)
-
Almacenamiento:
-80°C, protect from light
Actividad biológica
HLX43 induces tumor regression in multiple PD-L1+ CDX and PDX models, and was well tolerated across all dosing groups[2].
HLX43 (8 mg/kg, three times for a week) significantly reduces tumors in the MDA-MB-231 model without causing weight loss[2].
HLX43 shows well tolerability in rats and cynomolgus monkeys, with the maximum tolerated dose being 60 mg/kg in rats and 10 mg/kg in non-human primates[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
Appearance Liquid
-
Peso molecular 153714 (average)
-
Color Colorless to light yellow
-
SMILES
[HLX43]
-
Envío
Shipping with dry ice.
-
Almacenamiento
-80°C, protect from light
Pureza y Documentación
-
Ficha de datos (267 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)